In the context of CRC, monoclonal antibodies targeting at PD-1 such as nivolumab (Overman et al., 2017) and CTLA4 such as ipilimumab (Overman et al., 2018), exhibited high efficacy for the treatment of CRC patients with high microsatellite instability status. Here, CTLA4 is linked to colorectal carcinoma.